US Patent No: 7,875,677

Number of patents in Portfolio can not be more than 2000

Micellar drug delivery systems for hydrophobic drugs

ALSO PUBLISHED AS: 20090105351

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNIVERSITY OF BRITISH COLUMBIAVANCOUVER278

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Burt, Helen M Vancouver, CA 31 257
Jackson, John K Vancouver, CA 37 374
Zastre, Jason Vancouver, CA 4 6

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
5,843,891 Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug 33 1995
 
PROTHERICS SALT LAKE CITY, INC. (1)
6,592,899 PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water 17 2001
 
Gerhard Gergely (1)
5,834,019 Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system 7 1996
 
KIM PH.D., SUNG WAN (2)
6,004,573 Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 150 1997
6,117,949 Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 62 1998
 
CEPHALON LIMITED (1)
6,107,332 Hydrolysis-promoting hydrophobic taxane derivatives 3 1999
 
ANGIOTECH PHARMACEUTICALS, INC. (4)
5,886,026 Anti-angiogenic compositions and methods of use 234 1995
5,994,341 Anti-angiogenic Compositions and methods for the treatment of arthritis 72 1995
6,506,411 Anti-angiogenic compositions and methods of use 77 1999
6,544,544 Anti-angiogenic compositions and methods of use 140 2001
 
APHIOS CORPORATION (1)
5,776,486 Methods and apparatus for making liposomes containing hydrophobic drugs 37 1996
 
IPXMEDICAL, LLC (3)
6,515,016 Composition and methods of paclitaxel for treating psoriasis 32 1997
6,495,579 Method for treating multiple sclerosis 16 1998
6,689,803 Compositions and methods for treating surgical adhesions 77 2002
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,955,509 pH dependent polymer micelles 200 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
4,942,184 Water soluble, antineoplastic derivatives of taxol 157 1988
 
The Scripps Research Institute (2)
5,274,137 Intermediates for preparation of taxols 33 1992
5,422,364 Water soluble taxol derivatives 50 1993
 
ANGIOTECH BIOCOATINGS CORP. (1)
5,716,981 Anti-angiogenic compositions and methods of use 723 1995
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,543,158 Biodegradable injectable nanoparticles 296 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
5,968,972 Method for increasing the oral bioactivity of pharmaceutical agents 27 1996
 
Rhone-Poulenc S.A. (1)
5,453,521 Process for obtaining 10-deacetylbaccatin III 13 1993
 
Rhone-Poulenc Sante (1)
4,857,653 Process for the preparation of taxol and 10-deacetyltaxol 178 1987
 
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (4)
5,059,699 Water soluble derivatives of taxol 117 1990
5,352,805 Water soluble derivatives of taxol 17 1991
5,278,324 Water soluble derivatives of taxol 56 1991
5,411,984 Water soluble analogs and prodrugs of taxol 18 1992
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5,200,534 Process for the preparation of taxol and 10-deacetyltaxol 63 1992
 
Supernus Pharmaceuticals, Inc. (1)
5,430,021 Hydrophobic drug delivery systems 50 1994
 
BRISTOL-MYERS SQUIBB COMPANY (8)
5,248,796 Taxol derivatives 77 1992
5,300,638 Asymmetric synthesis of taxol side chain 31 1992
5,272,171 Phosphonooxy and carbonate derivatives of taxol 98 1992
5,254,580 7,8-cyclopropataxanes 119 1993
5,294,637 Fluoro taxols 68 1993
5,380,751 6,7-modified paclitaxels 37 1993
5,412,092 N-substituted 2-azetidinones 44 1993
5,395,850 6,7-epoxy paclitaxels 22 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (1)
4,650,913 Sulfinate-initiated addition of perfluorinated iodides to olefins 12 1984
 
CORNELL UNIVERSITY (1)
6,369,037 Controlled release of doxorubicin 2 2000
 
RESEARCH DEVELOPMENT CORPORATION OF JAPAN (1)
5,510,103 Physical trapping type polymeric micelle drug preparation 46 1995
 
SUPRATEK PHARMA INC. (1)
6,153,193 Compositions for targeting biological agents 12 1995
 
TEKMIRA PHARMACEUTICALS CORPORATION (1)
5,478,860 Stable microemulsions for hydrophobic compound delivery 55 1993
 
MAYNE PHARMA (USA), INC. (1)
5,202,448 Processes of converting taxanes into baccatin III 33 1992
 
EFRAT BIOPOLYMERS LTD. (1)
6,365,173 Stereocomplex polymeric carriers for drug delivery 41 1999
 
UNIVERSITY OF DELAWARE (1)
4,419,340 Controlled release of anticancer agents from biodegradable polymers 50 1980
 
SYNGENTA LIMITED (1)
4,745,160 Biodegradable amphipathic copolymers 141 1985
 
DUKE UNIVERSITY (1)
5,827,533 Liposomes containing active agents aggregated with lipid surfactants 35 1997
 
VESTAR, INC. (1)
5,484,809 Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid 48 1994
 
SUPERGEN, INC. (2)
6,017,948 Water-miscible pharmaceutical compositions 18 1998
6,136,846 Formulation for paclitaxel 42 1999
 
SUCAMPO AG (1)
5,229,529 Method of producing .alpha.,.beta.-unsaturated ketolactones 22 1992
 
AVENTIS PHARMA S.A. (6)
4,814,470 Taxol derivatives, their preparation and pharmaceutical compositions containing them 248 1987
5,393,895 Process for obtaining 10-deacetylbaccatin III 8 1993
5,393,896 Process for obtaining 10-deacetylbaccatin III 7 1993
5,717,103 Process for the esterification of baccatin III and of 10-deacetylbaccatin III 3 1995
5,736,366 Process for obtaining 10-deacetylbaccatin III 6 1995
5,977,375 Esters of baccatin III and 10-deacetylbaccatin III 1 1997
 
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (1)
5,279,949 Process for the isolation and purification of taxol and taxanes from Taxus spp 40 1992
 
ABRAXIS BIOSCIENCE, LLC (1)
5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 141 1996
 
PHARMACIA & UPJOHN S.P.A. (1)
5,362,831 Polymer-bound paclitaxel derivatives 103 1993
 
ABBOTT LABORATORIES (1)
5,440,056 9-deoxotaxane compounds 47 1994
 
SAMYANG BIOPHARMACEUTICALS CORPORATION (3)
6,210,717 Biodegradable mixed polymeric micelles for gene delivery 29 1998
6,322,805 Biodegradable polymeric micelle-type drug composition and method for the preparation thereof 43 2000
6,616,941 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof 15 2001
 
BOSTON SCIENTIFIC SCIMED, INC. (5)
5,811,447 Therapeutic inhibitor of vascular smooth muscle cells 199 1995
5,981,568 Therapeutic inhibitor of vascular smooth muscle cells 289 1997
6,306,421 Therapeutic inhibitor of vascular smooth muscle cells 88 1997
6,231,600 Stents with hybrid coating for medical devices 380 1999
6,358,989 Therapeutic inhibitor of vascular smooth muscle cells 49 1999
 
R.P. SCHERER CORPORATION (2)
5,645,856 Delivery systems for hydrophobic drugs 110 1995
5,827,541 Process for preparing solid pharmaceutical dosage forms of hydrophobic substances 26 1996
 
BIONUMERIK PHARMACEUTICALS, INC. (1)
6,040,330 Pharmaceutical formulations of taxanes 18 1999
 
BASF AKTIENGESELLSCHAFT (1)
5,939,454 Fungicidal mixtures of an oxime ether carboxylic acit amide with a dithiocarbamate 1 1998
 
IMPERIAL CHEMICAL INDUSTRIES PLC (1)
4,526,938 Continuous release formulations 262 1983
 
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (2)
5,350,866 10-desacetoxytaxol derivatives 72 1992
5,283,253 Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them 94 1992
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
8,858,965 Micelle encapsulation of a combination of therapeutic agents 0 2013
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
* 2011/0287,085 LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER 0 2011
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 25, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 25, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00